CEPI will expand its partnership with icddr,b in Bangladesh, providing near to the additional US $ 1 million in funding to advance understanding of the Nipah virus
CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan
It plans to deliver over 300 million doses to the Indian government
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
The country’s vaccine production has more than doubled since April and is set to touch 300 million doses next month
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)